PDCD1 and non-small cell lung carcinoma: Clinical studies have confirmed that the combination of ABT.888 (veliparib) with PD-1 inhibitor plus platinum-based doublet chemotherapy demonstrates promising therapeutic efficacy in patients with metastatic or advanced non-small cell lung cancer [70].